---
title: "Forte Biosciences präsentiert auf Investorenkonferenzen in New York, Boston und Miami"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275360789.md"
datetime: "2026-02-09T21:01:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275360789.md)
  - [en](https://longbridge.com/en/news/275360789.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275360789.md)
---

# Forte Biosciences präsentiert auf Investorenkonferenzen in New York, Boston und Miami

Forte Biosciences, Inc. wird am 11. Februar 2024 am Guggenheim Emerging Outlook: Biotech Summit in New York teilnehmen, am 4. März 2024 an der TD Cowen 46th Annual Healthcare Conference in Boston präsentieren und vom 10. bis 12. März 2024 an der Barclays 28th Annual Global Healthcare Conference in Miami Beach teilnehmen. Weitere Informationen unter here. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209147037) on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [Alkermes reports sustained Phase 2 alixorexton benefits in narcolepsy type 1 study](https://longbridge.com/en/news/282986226.md)
- [08:00 ETLynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA](https://longbridge.com/en/news/282340368.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)